S&P 500 Futures
(-0.05%) 5 475.50 points
Dow Jones Futures
(-0.11%) 38 777 points
Nasdaq Futures
(-0.01%) 19 919 points
Oil
(0.15%) $80.45
Gas
(1.29%) $2.82
Gold
(0.21%) $2 333.80
Silver
(-0.24%) $29.32
Platinum
(-0.23%) $968.70
USD/EUR
(0.01%) $0.932
USD/NOK
(-0.18%) $10.63
USD/GBP
(0.05%) $0.788
USD/RUB
(-1.87%) $86.80

Realaus laiko atnaujinimai Iovance Biotherapeutics [IOVA]

Birža: NASDAQ Sektorius: Healthcare Pramonė: Biotechnology
Atnaujinta17 birž. 2024 @ 23:00

-0.98% $ 8.08

Live Chart Being Loaded With Signals

Commentary (17 birž. 2024 @ 23:00):
Our systems believe the stock currently is overvalued by -0.08% compare to its pairs and should correct downwards.

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells...

Stats
Šios dienos apimtis 5.67M
Vidutinė apimtis 5.71M
Rinkos kapitalizacija 2.26B
EPS $-0.420 ( Q1 | 2024-05-09 )
Kita pelno data ( $0 ) 2024-08-06
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -4.46
(Sector) 42.63
(Industry) 24.32
ATR14 $0.0130 (0.16%)
AADI -3.55%
ABCL -5.26%
ABCM 0.04%
ABEO -1.31%
ABIO -1.53%
ABOS -5.30%
ABSI -14.32%
ABUS -2.55%
ABVX -0.22%
ACAD -0.47%
ACER -17.95%
ACET -2.22%
ACGN 1.29%
ACHL 0.23%
ACHV 1.63%
ACIU -4.23%
ACLX -1.21%
ACRV -5.10%
ACST 0.62%
ACXP -0.42%
ADAG -5.64%
ADAP -7.23%
ADGI 0.87%
ADIL -2.29%
ADMA -1.79%
ADPT 0.32%
ADTX -7.69%
ADVM -3.94%
ADXN -6.11%
AEON 11.51%
AEZS -5.44%
AFMD -5.07%
AGEN -7.50%
AGIO -3.45%
AGLE 6.66%
AGTC 0.00%
AIKI 0.85%
AIMDW 53.45%
AKBA -1.87%
AKRO -4.46%
AKTX -6.33%
AKUS 0.00%
ALBO 0.00%
ALDX -1.34%
ALEC -2.35%
ALGS -5.76%
ALKS 2.08%
ALLK 0.86%
ALLO -2.13%
ALLR -3.01%
ALNA 3.16%
ALNY -1.93%
ALPN 0.00%
ALPX 0.00%
ALRN -0.31%
ALT -3.11%
ALVR -4.43%
ALXN 0.00%
ALXO -8.32%
ALZN -12.01%
AMRN -2.58%
AMTI -3.13%
ANAB -1.64%
ANEB -5.58%
ANGN 0.00%
ANIX -0.38%
ANL 0.61%
ANNX -4.63%
ANPC -3.15%
APGE -5.23%
APGN 8.48%
APGNW 30.65%
APLM -4.73%
APLS -3.98%
APLT -4.36%
APM 1.33%
APOP 0.38%
APRE 2.44%
APTO -3.96%
APTX 3.17%
APVO -20.53%
ARAV -13.39%
ARCT -9.26%
ARDS 20.48%
ARDX -0.94%
ARGX -2.25%
ARNA 0.00%
ARPO -0.90%
ARQT -7.76%
ARTL -0.38%
ARTLW 9.80%
ARVN -2.84%
ARWR -2.86%
ASLN -12.17%
ASMB -1.49%
ASND -2.39%
ATAI -2.19%
ATHA 2.36%
ATHE -1.61%
ATHX -33.50%
ATNF 15.09%
ATOS -4.17%
ATRA -16.93%
ATXI -1.66%
ATXS -3.50%
AUPH -1.95%
AURA 0.96%
AUTL -4.22%
AVBP -1.02%
AVEO 0.00%
AVIR -2.22%
AVRO 2.10%
AVTE -93.30%
AVTX 4.08%
AVXL -1.06%
AXLA 0.00%
AXSM 3.22%
AYLA 0.00%
AZRX 2.07%
BBI 2.17%
BBIO -2.26%
BCAB -1.89%
BCDA -2.05%
BCDAW -33.33%
BCEL -1.32%
BCLI -8.47%
BCRX 1.13%
BCTX 4.96%
BCTXW 0.00%
BCYC -4.33%
BDRX 1.89%
BDTX -8.38%
BEAM -3.38%
BFRA -2.91%
BGNE -1.97%
BIOR -10.12%
BIVI 0.41%
BLCM -6.68%
BLI -5.88%
BLPH -0.79%
BLRX -3.79%
BLTE -0.72%
BLU 0.03%
BLUE -0.77%
BMEA -9.75%
BMRN 1.81%
BNOX 1.64%
BNTC 2.46%
BNTX -3.95%
BOLD -5.95%
BOLT -0.82%
BPMC -1.59%
BPTH 10.65%
BPTS -13.47%
BRNS -6.63%
BRTX 20.00%
BTAI -2.92%
BTTX -7.50%
BTX 0.05%
BVXV 0.74%
BXRX 7.39%
BYSI 6.06%
CABA -12.20%
CADL -0.96%
CALA 60.00%
CALC -1.62%
CALT 0.03%
CAPR -4.06%
CARA -27.26%
CARM -9.65%
CASI -8.04%
CATB -6.97%
CBAY 0.03%
CBIO -2.65%
CBLI -7.31%
CBUS 3.07%
CCCC -5.48%
CCXI 0.00%
CDAK 0.00%
CDIO -1.51%
CDIOW -23.08%
CDMO 5.72%
CDMOP 0.04%
CDT -6.11%
CDTTW -47.71%
CDTX -6.32%
CDXC -0.67%
CDXS -2.30%
CELC -2.79%
CELU -2.19%
CELUW -9.52%
CERC -1.68%
CERE -0.16%
CERO -7.87%
CEROW -44.78%
CFRX -27.95%
CGEM 0.74%
CGEN -5.31%
CGON -2.68%
CGTX 0.92%
CHMA -6.00%
CHRS -2.96%
CINC 0.00%
CING -1.09%
CINGW -48.24%
CKPT -4.25%
CLBS -16.75%
CLDX 0.69%
CLGN 1.19%
CLLS -4.89%
CLNN -2.48%
CLNNW -41.25%
CLRB -9.94%
CLSD -0.84%
CLSN -0.68%
CLVS 0.00%
CMMB -24.79%
CMND 1.83%
CMPI 0.00%
CMPX 5.41%
CMRA 0.40%
CMRAW 33.33%
CMRX 1.44%
CNCE 0.00%
CNSP 3.94%
CNST 0.00%
CNTA -6.39%
CNTB 3.13%
CNTX -1.02%
COCP -0.16%
COEPW -0.66%
COGT 4.45%
CORT -1.31%
COYA -6.11%
CPRX -0.40%
CRBP -11.76%
CRBU -2.23%
CRDF -1.11%
CRGX -4.78%
CRIS 1.11%
CRNX -1.37%
CRSP -2.79%
CRTX 2.63%
CRVO -1.89%
CRVS -5.39%
CSBR 1.19%
CTCX -8.04%
CTIC 0.06%
CTMX -0.72%
CTNM 0.00%
CTXR -1.50%
CUE -1.47%
CVAC -5.18%
CVKD 3.18%
CWBR -2.55%
CYAD -12.96%
CYCC -3.55%
CYCCP -1.79%
CYCN 6.00%
CYT -2.27%
CYTK -2.13%
CYTO 2.48%
DARE -3.31%
DAWN -4.60%
DBTX -0.81%
DBVT 1.01%
DFFN 10.28%
DICE 0.06%
DMAC -0.42%
DNLI -1.21%
DNTH -2.85%
DOMH 1.99%
DRMA 0.00%
DRMAW 0.00%
DRNA 0.00%
DRTS -1.32%
DRTSW 1.01%
DRUG 0.00%
DSGN 2.97%
DTIL -2.07%
DYAI -5.29%
EARS -1.77%
EDIT 0.20%
EDSA 1.04%
EFTR -3.13%
EFTRW -0.26%
EIGR 0.00%
ELAB 1.44%
ELDN -6.93%
ELEV -7.89%
ELOX -12.50%
ELTX -2.33%
ELVN -0.65%
ELYM -13.05%
ENGN -3.89%
ENGNW -7.06%
ENLV -3.47%
ENOB 1.79%
ENSC -0.55%
ENTA -6.00%
ENTO -2.80%
ENTX 0.00%
ENVB -4.64%
EPIX -8.75%
EPRX -0.19%
EPZM 0.00%
EQ 0.50%
EQRX -2.09%
EQRXW 0.00%
ERAS -7.83%
ERNA 2.60%
ERYP 1.30%
ESLA -6.38%
ESLAW -9.25%
ETNB 1.03%
ETON -5.90%
ETTX 0.00%
EVAX -19.54%
EVGN -2.14%
EVLO 50.00%
EWTX -0.80%
EXAI 1.19%
EXEL 0.18%
EYEG -0.43%
EYEN 1.57%
EYPT -3.94%
FATE -1.11%
FBIO 1.60%
FBIOP -1.05%
FBLG -5.34%
FBRX -7.46%
FDMT 0.72%
FENC 0.74%
FGEN -5.36%
FHTX 9.52%
FIXX 0.77%
FMTX 0.00%
FNCH -6.25%
FOLD -0.99%
FREQ 4.76%
FRLN 0.15%
FRTX -0.54%
FSTX 0.00%
FTRE 0.38%
FULC -6.04%
FUSN 0.00%
FWBI 4.59%
FWP 0.00%
GALT -4.58%
GANX 6.45%
GBIO 6.57%
GBT 0.01%
GDTC 2.16%
GERN -4.11%
GHRS 3.42%
GLMD -6.66%
GLPG 1.18%
GLSI 18.16%
GLTO -4.90%
GLUE -4.18%
GLYC -9.70%
GMAB -1.57%
GMDA 0.00%
GMTX 0.00%
GNCA -85.71%
GNFT 0.14%
GNLX 1.27%
GNPX 1.84%
GNTA -0.60%
GOSS 0.02%
GOVX -7.50%
GOVXW -24.72%
GPCR 0.85%
GRAY -10.80%
GRCL 0.05%
GRNA -0.03%
GRNAW 8.91%
GRPH -2.75%
GRTS -2.71%
GRTX -4.26%
GTHX -3.96%
GUTS -3.90%
GXGXW 41.67%
GYRE 4.44%
HALO 0.32%
HARP 0.09%
HCWB -9.73%
HEPA -6.36%
HGEN -84.62%
HILS 5.66%
HLVX 1.33%
HOOK -4.04%
HOTH -3.73%
HOWL 3.99%
HRMY 1.10%
HRTX -10.42%
HSTO 62.16%
HUMA -12.20%
HUMAW -5.97%
IBRX -2.18%
ICCC 2.84%
ICPT 0.21%
ICU 1.30%
ICUCW -10.39%
ICVX -0.91%
IDRA -23.04%
IDYA -1.44%
IFRX -3.21%
IGMS 0.41%
IKNA -0.57%
IKT 8.90%
IMAB -1.09%
IMCR -3.82%
IMGN 0.02%
IMGO 0.00%
IMMP -0.74%
IMMX -0.49%
IMNM -11.86%
IMNN -1.80%
IMPL -27.27%
IMRA 15.96%
IMRN -2.78%
IMRX 1.66%
IMTX -0.08%
IMTXW -2.70%
IMUX -4.20%
IMV 0.00%
IMVT 3.08%
INAB -8.26%
INBX -9.62%
INCY 0.93%
INDP 7.98%
INFI -52.38%
INKT -1.05%
INM -2.58%
INMB -2.47%
INO -1.65%
INSM 1.22%
INTS -5.63%
INVA 1.57%
INZY -2.95%
IOBT -6.11%
IONS 0.27%
IOVA -0.98%
IPA 0.48%
IPHA -10.64%
IPSC 0.64%
IRON -3.05%
ISEE 0.38%
ITOS -6.04%
ITRM -1.74%
IVA -10.10%
IVVD -6.96%
JAGX -6.67%
JANX -4.57%
JAZZ 1.43%
JNCE 0.00%
JSPR -2.80%
JSPRW 2.33%
JUNS 0.00%
JUNSW 0%
KA 4.11%
KALV -2.07%
KDNY 0.22%
KMPH -0.34%
KNSA -1.28%
KNTE -0.38%
KOD -4.27%
KPRX -21.08%
KPTI 1.69%
KRBP 4.17%
KRON -3.70%
KROS -9.68%
KRRO -16.54%
KRTX 0.03%
KRYS -0.04%
KTRA -2.35%
KTTA -2.85%
KTTAW 8.62%
KURA -0.62%
KYMR -4.42%
KYTX -17.21%
KZIA -1.29%
KZR -2.71%
LABP 0.57%
LBPH 1.67%
LBPS 0.00%
LBPSW 14.81%
LEGN -2.24%
LENZ -0.54%
LEXX -5.18%
LEXXW -9.42%
LGND 0.72%
LGNDV 0.00%
LGVN -24.76%
LIAN 0.00%
LIFE 2.70%
LIPO -1.23%
LIXT 0.40%
LIXTW 27.74%
LJPC -0.32%
LMNL 0.12%
LOGC 2.76%
LPCN 12.64%
LPTX -1.90%
LQDA 3.01%
LRMR -14.91%
LSTA -4.97%
LTRN -8.57%
LUMO -2.95%
LVTX -9.52%
LXEO -6.50%
LXRX -5.49%
LYEL -8.05%
LYRA -8.37%
MACK 0.00%
MBIO 476.92%
MBRX -4.83%
MCRB -5.28%
MDGL -0.31%
MDNA -13.16%
MDWD 1.00%
MDXG 0.59%
MEIP 1.41%
MESO -0.55%
MGNX -4.03%
MGTA -7.74%
MGTX -2.23%
MGX -24.14%
MIRM 27.31%
MIRO 0.59%
MIST -1.42%
MITO 0.00%
MLEC -4.55%
MLECW 9.20%
MLND -5.36%
MLTX -2.99%
MLYS -3.02%
MNKD -1.04%
MNMD -3.36%
MNOV 0.00%
MNPR -8.51%
MOLN 8.81%
MOR 0.88%
MORF -1.25%
MREO 0.00%
MRKR 16.59%
MRNA -1.52%
MRNS -1.02%
MRSN -1.45%
MRTX -0.17%
MRUS -1.38%
MRVI -3.99%
MTCR -1.29%
MTEM 1.54%
MTP -18.50%
MURA 2.17%
MYMD 4.19%
NAMS -7.03%
NAMSW -7.61%
NAUT 0.00%
NBRV 0.71%
NBSE -1.56%
NBTX 4.77%
NCNA -1.64%
NERV 8.96%
NEXI 0.00%
NGM -1.28%
NGNE -6.08%
NKGN -4.44%
NKGNW 39.76%
NKTR 0.00%
NKTX -5.66%
NLSP 30.09%
NLSPW -16.67%
NMRA -4.09%
NMTR -42.97%
NOVN -24.84%
NRBO 0.45%
NRIX 0.72%
NRSN -3.82%
NRSNW 6.50%
NRXP 0.99%
NRXPW -15.65%
NRXS -6.06%
NTBL 13.82%
NTEC -12.45%
NTHI 0%
NTLA 0.08%
NTRBW -6.25%
NUVL -0.77%
NVAX -2.43%
NVCT 1.18%
NVIV -34.28%
NXTC -10.63%
NYMX -0.05%
OABI 0.95%
OABIW 13.46%
OBIO 0.88%
OBSV 0.00%
OCEA 10.64%
OCGN -5.63%
OCS -1.09%
OCUL -4.35%
OCUP 1.82%
ODT -4.27%
OKYO 0.00%
OLMA -3.96%
OMER -0.49%
OMGA -8.37%
ONCO 12.54%
ONCR -3.08%
ONCS 31.87%
ONCT -0.12%
ONCY -0.98%
ONTX -0.47%
ONVO 0.62%
OPNT 0.00%
OPT -5.51%
ORGS -1.72%
ORIC -0.67%
ORMP -0.44%
ORPH 0.00%
ORTX 0.30%
OSMT -1.77%
OTIC -92.64%
OTLK -1.43%
OVID -76.00%
OYST 0.00%
PALI 0.86%
PASG -3.81%
PBLA 9.76%
PBM -0.02%
PBYI 2.89%
PCSA 5.71%
PCVX -1.45%
PDSB -4.13%
PEPG 0.70%
PGEN 0.00%
PHAR 2.17%
PHAS 0.00%
PHAT 3.08%
PHIO 4.14%
PHIOW 36.47%
PHVS -0.53%
PHXM -5.20%
PIRS -5.64%
PKBO 0.00%
PKBOW 999 900.00%
PLRX -5.08%
PLUR 0.00%
PMN -5.59%
PMVP -1.20%
PNT 0.16%
PPBT -11.48%
PRAX -6.21%
PRDS 0.93%
PRLD 0.77%
PROG -3.47%
PROK 6.96%
PRQR -3.41%
PRTA -0.20%
PRTC -0.72%
PRTG -1.96%
PRTK 1.83%
PRVB 0.00%
PSTI -2.91%
PSTV 0.00%
PSTX 1.81%
PTCT -1.14%
PTE -0.82%
PTGX -2.76%
PTIXW 2.50%
PULM 3.72%
PXMD -1.92%
PYPD -0.36%
PYXS -3.43%
QLGN -11.72%
QNCX 0.00%
QNRX -10.97%
QSI -2.92%
QSIAW 0.00%
QTTB 3.82%
QURE -4.09%
RAIN -1.63%
RANI -5.46%
RAPT -0.30%
RARE 1.92%
RCKT -3.02%
REGN 0.85%
RENB -3.05%
REPL -6.63%
RETA 0.02%
REUN -0.89%
REVB 1.36%
REVBU 3.46%
REVBW 25.20%
RGLS -1.66%
RGNX -6.20%
RIGL -2.79%
RLAY -3.01%
RLMD -0.33%
RLYB -6.15%
RNA -0.10%
RNAC -14.55%
RNAZ -5.83%
RNXT 14.41%
ROIV 0.28%
ROIVW 4.56%
RPHM -0.60%
RPRX -1.15%
RPTX 0.00%
RUBY 2.70%
RVLP -32.05%
RVMD -3.94%
RVMDW -23.93%
RVNC -0.71%
RVPH -0.68%
RVPHW 11.54%
RXDX 0.09%
RXRX 1.19%
RYTM -3.76%
RYZB 0.02%
RZLT -2.53%
SABS 3.17%
SABSW -32.14%
SAGE -6.08%
SANA -1.32%
SAVA 0.81%
SAVAW 0.00%
SBBP 1.52%
SBTX 1.03%
SCNI 60.46%
SCPH -1.69%
SCPS 0.00%
SEEL -4.62%
SEER -3.37%
SELB -8.00%
SESN 7.29%
SGEN -0.07%
SGMO -17.30%
SGMT 1.93%
SGTX -2.56%
SIOX 22.63%
SLDB -5.44%
SLGL -2.22%
SLN -1.55%
SLNO 0.19%
SLRX 2.89%
SLS -16.67%
SMMT -5.84%
SNDX -1.14%
SNGX -5.91%
SNPX -3.97%
SONN -4.75%
SPPI -0.49%
SPRB 0.49%
SPRC -3.16%
SPRO -5.88%
SRNE 20.00%
SRPT -4.89%
SRRA 0.00%
SRRK -7.09%
SRZN -1.70%
STAB 0.00%
STOK -4.00%
STRO -7.51%
STSA 0.00%
STTK -19.55%
SURF -0.93%
SVRA -5.15%
SWTX -4.88%
SYBX -0.63%
SYRS -4.83%
TALS -0.73%
TARA -0.78%
TARS -6.91%
TBPH -0.59%
TCBP -8.64%
TCDA 0.00%
TCON 6.35%
TCRR 0.00%
TCRT 1.05%
TCRX -11.43%
TECH -1.40%
TENX -3.43%
TERN -2.93%
TFFP 0.52%
TGTX 0.12%
THRX 0.12%
TIL -2.06%
TLC 0.00%
TLSA 5.78%
TNGX 5.04%
TNXP -2.61%
TNYA -1.79%
TPST 0.34%
TRDA -3.61%
TRVI 2.08%
TRVN -1.88%
TSHA 1.51%
TSVT 3.29%
TTNP 1.45%
TVTX 2.23%
TYRA -8.69%
UBX -4.17%
UNCY 0.22%
URGN -4.79%
UTHR 3.12%
VACC 11.36%
VALN -1.55%
VAXX -0.11%
VBIV -3.61%
VBLT -8.77%
VCEL -1.37%
VCNX -3.70%
VCYT 1.96%
VERA -0.83%
VERU 2.29%
VERV -2.77%
VIGL -2.08%
VINC -4.90%
VIR -5.85%
VIRI 4.95%
VIRX -3.62%
VKTX 0.00%
VLON -13.04%
VNDA 1.76%
VOR 1.74%
VRCA 0.49%
VRDN -1.93%
VRNA 10.04%
VRPX 10.77%
VRTX -1.46%
VSTM 0.00%
VTGN -2.84%
VTVT -0.10%
VTYX -4.51%
VXRT -8.25%
VYGR -2.94%
VYNE 2.16%
VYNT 7.78%
WINT 7.98%
WVE -3.85%
XBIO 6.75%
XBIT -0.33%
XCUR -3.10%
XENE -1.75%
XERS -0.91%
XFOR -2.75%
XLO -6.86%
XLRN 0.00%
XNCR -5.15%
XOMA -4.31%
XOMAO 0.68%
XOMAP -0.14%
XRTX 1.96%
YMAB -1.34%
ZGNX 0.00%
ZIOP -0.88%
ZLAB 1.55%
ZNTL -5.09%
ZSAN 0.00%
Insider Trading
Date Person Action Amount type
2024-06-11 Countouriotis Athena Buy 49 303 Deferred Restricted Stock Unit
2024-06-11 Yarno Wendy L Buy 49 303 Deferred Restricted Stock Unit
2024-06-11 Weiser Michael Buy 49 303 Deferred Restricted Stock Unit
2024-06-11 Maynard Ryan D Buy 49 303 Deferred Restricted Stock Unit
2024-06-11 Dukes Iain D. Buy 98 607 Deferred Restricted Stock Unit
INSIDER POWER
95.32
Last 99 transactions
Buy: 13 500 253 | Sell: 312 775
Koreliacija (AI algo v.1.1b): Overvalued: -0.08% $8.08 paired level. (Algoritmas realiuoju laiku stebi didžiausią koreliaciją turinčių akcijų pokyčius ir suteikia momentinę informaciją)

Tūris Koreliacija

Ilgas: -0.03 (neutral)
Trumpas: 0.23 (neutral)
Signal:(54.268) Neutral

Iovance Biotherapeutics Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
LRMR0.904
EQ0.9
CFLT0.898
TARA0.883
NTWK0.864
FROG0.86
TRMB0.86
CLBT0.855
PXLW0.853
ALRM0.852
10 Labiausiai neigiamai susiję koreliacijos
BLKB-0.908
SSRM-0.874
CAR-0.842
FINW-0.842
DSWL-0.827
CYAN-0.825
EGAN-0.823
BIOL-0.821
SGLY-0.817
WTER-0.812

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Iovance Biotherapeutics Koreliacija - Valiuta/Žaliavos

The country flag 0.27
( neutral )
The country flag 0.10
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag -0.08
( neutral )

Iovance Biotherapeutics Finansinės ataskaitos

Annual 2023
Pajamos: $1.19M
Bruto pelnas: $-31.94M (-2 686.12 %)
EPS: $-1.890
FY 2023
Pajamos: $1.19M
Bruto pelnas: $-31.94M (-2 686.12 %)
EPS: $-1.890
FY 2022
Pajamos: $0
Bruto pelnas: $-21.14M (0.00 %)
EPS: $-2.45
FY 2021
Pajamos: $0.00
Bruto pelnas: $0.00 (0.00 %)
EPS: $-2.20

Financial Reports:

No articles found.

Iovance Biotherapeutics Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Iovance Biotherapeutics

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Apie Signalai gyvai

Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.

Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.

Total Execution Time: 2.165913105011 seconds
Number of API calls: 3
Number of DB calls: 9